USA: The RECOVER Initiative - Long Covid research

forestglip said:
https://recovercovid.org/r3-seminar-series

April 08, 2025
12:00PM Eastern Time

Effectiveness of Paxlovid in Protecting Against Long COVID: EHR Insights
Speakers will present findings from two studies examining whether Paxlovid treatment in the acute phase of COVID-19 helps to prevent Long COVID. The study teams used electronic health records from the National Covid Cohort Collaborative (N3C) and the National Patient-Centered Clinical Research Networks (PCORnet) RECOVER repository.

Register for the seminar
Click to expand...
Reminder that this starts in 1.5 hours.
 
They presented findings from two large observational studies of Paxlovid use during acute COVID, using a "Target Trial Emulation" methodology, which is an attempt to emulate an RCT as much as possible using observational data. They use statistical methods such as "Inverse Probability of Treatment Weighting" to control for as many possible confounders as possible.

PCORnet (see thread for study)
For the PCORnet study, they studied 497,499 patients. Paxlovid treatment was required to be within 5 days of infection.
159,659 high risk received treatment
5,597 low risk received treatment
272,048 high risk did not receive treatment
35,874 low risk did not receive treatment
​
When looking at incidence of long COVID over 180 days after infection, they found that about 3 fewer people developed long COVID per 100 people that were infected when taking Paxlovid. The hazard ratio was 0.88. (12% less likely to develop long COVID). Also found decreased incidence of hospitalization greater than 30 days after infection and decreased mortality with Paxlovid use.

They looked at the effect of Paxlovid on specific long COVID symptoms in various categories (neurologic, skin, pulmonary, etc). The hazard ratio is significantly less than 1 in almost every category (Paxlovid associated with decreased risk of LC). The two exceptions that were not significant were associations with hair loss and with receiving the long COVID diagnostic code U09.9.

They also looked separately at high risk and low risk patients. High risk means older age (≥ 50), smoker, or underlying conditions such as cancer or diabetes. There was a significant association of Paxlovid with decreased LC in high risk, but not low risk patients. When splitting by factors such as specific condition or age in the high risk population, the hazard ratios are still almost consistently significant when grouping based on these factors.

N3C (see thread for study)
This study on the N3C cohort also found decreased risk of long COVID with Paxlovid use. 1 fewer person per 366 infected when treated with Paxlovid [about 0.27 per 100 when comparing to 2.99 per 100 in PCORnet cohort].

There was a lower risk of long COVID when looking at the overall definition (RR=0.94, 95% CI: 0.92-0.97). When splitting by symptom clusters, there was significant decrease for cognitive phenotype (RR=0.86, 95% CI: 0.81-0.91) and fatigue/malaise phenotype (RR=0.92, 95% CI: 0.88-0.96), but not respiratory phenotype (RR=1.03, 95% CI: 0.97-1.09).

Also corroborated previously published findings about Paxlovid reducing risk of hospitalization and death.

-----

The findings were fairly close for relative risk between the cohorts showing a modest reduction in risk of long COVID in those who take Paxlovid during acute COVID infection, specifically in high risk patients.

The differences in absolute risk reduction were likely due to the different definitions used for long COVID. About 30% of people developed LC using rule-based PCORnet definition, versus only about 5% using machine learning-based N3C definition.

Edit: Fixed typo in relative risk value for fatigue/malaise phenotype.
 
Last edited:
1/30/25 - Univ. of Alabama Birmingham (UAB), Dept. of Pathology: 'Benson secures RECOVER grant to study effects of Long COVID'

'The grant will fund $158,000 per year and will run through April 2026.'

'Paul Benson, M.D., Professor and Autopsy Section Head in the Department of Pathology's Division of Anatomic Pathology, was awarded a Researching COVID to Enhance Recovery (RECOVER) grant from the National Institutes of Health for his project, titled, "A Multi-site Pathology Study of Post-Acute Sequelae of SARS-CoV-2 Infection'

"We believe the RECOVER tissue pathology (autopsy) study will inform Long COVID research and treatment options for years to come," Benson said.

'Autopsies will be performed to address the pathophysiology of the potential long-term effects of SARS-CoV-2 infection on human health'
 
Dakota15 said:
1/30/25 - Univ. of Alabama Birmingham (UAB), Dept. of Pathology: 'Benson secures RECOVER grant to study effects of Long COVID'

'The grant will fund $158,000 per year and will run through April 2026.'

'Paul Benson, M.D., Professor and Autopsy Section Head in the Department of Pathology's Division of Anatomic Pathology, was awarded a Researching COVID to Enhance Recovery (RECOVER) grant from the National Institutes of Health for his project, titled, "A Multi-site Pathology Study of Post-Acute Sequelae of SARS-CoV-2 Infection'

"We believe the RECOVER tissue pathology (autopsy) study will inform Long COVID research and treatment options for years to come," Benson said.

'Autopsies will be performed to address the pathophysiology of the potential long-term effects of SARS-CoV-2 infection on human health'
Click to expand...
Weren't all those RECOVER grants cancelled by the new administration?
 
R3 Seminar Recap: Effectiveness of Paxlovid in Protecting Against Long COVID: EHR Insights

'Mr. Bhatia noted that the results from the two studies are complementary and reach a consensus that Paxlovid can help reduce the risk of Long COVID. Both studies are currently in pre-print, which means they are publicly available online while the results continue to be peer-reviewed by other researchers to confirm accuracy and scientific rigor. Mr. Bhatia also recommended that future research should account for the wide range of symptoms associated with Long COVID and explore tailored treatments for different symptoms.

Studies that analyze EHR data do have limitations, Dr. Wang explained. For example, structured EHR data may be incomplete, and researchers do not have a way to determine whether people actually took Paxlovid after being prescribed the medication. However, EHR studies allow researchers to examine large groups of people from all walks of life, meaning that results will be relevant for a wide range of people.'
 
Dakota15 said:
May 13 RECOVER webinar: 'Understanding metformin use and Long COVID and ME/CFS following COVID-19 infection: Insights from two studies'
Click to expand...

Join RECOVER for the next R3 Seminar, Understanding Metformin Use and Long COVID and ME/CFS following COVID-19 Infection: Insights from Two Studies, to be held Tuesday, May 13, 2025, at 12:00-1:30 pm ET.

RECOVER investigators will present findings about the association between metformin use and the incidence of Long COVID using the EHR-based cohort study. The speakers will also present findings about the incidence and prevalence of myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) following COVID-19 infection using the adult observational cohort study.

Panelists for the seminar include:
  • Steve Johnson, University of Minnesota
  • Carolyn Bramante, University of Minnesota
  • Suzanne Vernon, Bateman Home Center
  • Yu Chen, NYU Langone Health
 
5/8/25, 'ACP Long COVID Interest Group - Dr. Linda Geng (Stanford)'

Geng: "RECOVER Initiative has some of the biggest platform trials and different trials for different phenotypes right now and then there should be another hopefully, to launch soon, the second phase of the trials called RECOVER-TLC or Treating Long COVID. I'm excited to see hopefully what agents will be chosen for that next round of trials. And then currently and previously, part of the original phrase of the clinical trials under RECOVER, we were running trials testing for example, transcranial stimulation, as well brain HQ and other interventions for brain fog. There's a trial we're running right now testing Ivabradine and other sites are testing potentially IVIG for the POTS phenotype, there's another trial running right now for exercise intolerance and sleep, so there's lots of trials underway. And I know there's nationally trials testing other anti-inflammatory agents and of course there's tons of trials that are registered, so this is definitely not comprehensive by any means, but I think the big categories that I'm really interested to see are those anti-inflammatory agents, immune modulators, potentially neurological agents, cardiovascular agents as as well as again non-pharmacologic strategies and possibly combining some of these therapies may be also the ultimate answer."
 
Daily Herald [Chicago]: '‘I’m still battling this’: Endeavor Health recruiting patients for long-COVID studies'

'Endeavor Health, formerly NorthShore University HealthSystem, has been part of multiple long-COVID studies conducted through Researching COVID to Enhance Recovery, or RECOVER, a nationwide research program established by the National Institutes of Health.'

'Shah expects some answers “very soon.”

“The only way I can explain it is like you feel like you hit a brick wall, because all of a sudden you need to lay down,” the Buffalo Grove woman said.

'“It could be brain fog and all these neurologic-type issues. It could be cardiopulmonary issues related to exercise intolerance.'

“You probably know someone that has had long COVID, really, if it’s 8% of the population, 20 million people,” Shah said. “..there are these cases where…they just can’t function anymore, and they’re not getting better …"

“the sooner we have answers,” she said, “the sooner we can all move on with our lives.”
 
5/15/25, Stanford Medicine: 'The Engine of Innovation: Ten Years of SCCR at Stanford Medicine'

'SCCR has played a key role in the NIH RECOVER initiative, one of the largest studies of Long COVID in the nation. With more than 1,000 participants enrolled at Stanford and SHC Tri-Valley, the team is leading several intervention sub-studies exploring treatments for brain fog, autonomic dysfunction, and post-exertional malaise.'
 
NIH Oral History: 'Rebecca Letts (2023)'

'Ms. Letts is a Long COVID patient as well as a Long COVID advocate who is affiliated with the NIH's RECOVER program'

Letts: "My brain doesn't work, I'll be talking about ones that pop into my head or ones I've written down. But first of all, pain. I have so many kinds of pain. I have small-fiber neuropathy, which itself encompasses a lot of different kinds of pain, migraines, GI, so gastrointestinal pain, joint pain...one more really bad symptom is post-exertional malaise. That means that just doing, thinking, or feeling too much can make my symptoms get worse in the future.'

'My other chronic conditions, that either were triggered by Long COVID or exacerbated by Long COVID, are worse for that time period. For example, ME/CFS [myalgic encephalomyelitis/chronic fatigue syndrome] is the one that with the post-exertional malaise.'

'I also have POTs [postural orthostatic tachycardia syndrome], which is a dysautonomia, an autonomic dysfunction. I get a whole range of symptoms but the most obvious to the outside world is fainting or really bad dizziness and temperature-regulation dysfunction'

'And cognitive impairment is a huge one...It is more like there's something actually wrong and missing kind of, but it's not all the time. It can vary how much and so I have executive dysfunction really badly'

'I feel like the patient communities are very clear about—there is extensive past research about ME/CFS and POTS that has already been done. It would be really beneficial to start at a point where some of that [work] has already been done and not from scratch. Yet, that seems to be ignored. There are some things that we really don't want RECOVER to focus on, both for the way it looks to the greater world that really respects what comes out of NIH, to also what is a good use of resources and funding. We're desperate. We are living in a situation where we really need help. It feels like RECOVER isn't taking that seriously. They say they are, but the actions aren't saying the same thing.'

' I think we do need help. We need treatment and recognition. It's really important—and I think a lot of us wonder if this is going to happen at this point..'

"I think the medical system has to be reworked. It's not serving chronic illness patients well....but what I've learned with RECOVER, is that it's really important to remember "Nothing about us without us."
 
VCU Health: 'Unlocking the puzzle of persistent symptoms of long COVID and POTS in children'

'VCU researchers investigating the causes of persistent symptoms in two perplexing post-viral conditions in pediatric populations to improve future treatments.'

'With funding from the NIH’s Researching COVID to Enhance Recovery (RECOVER) Initiative and support from their pathobiology research program, researchers at Virginia Commonwealth University are investigating the brain-body connections that may help explain these conditions in pediatric populations'

'Researchers will analyze data from two initiatives: NIH RECOVER, which aims to better understand, diagnose, prevent and treat long COVID and an existing POTS study funded by the NIH, focused on adolescent populations'

“Specifically, we believe that both of these disorders occur when ‘emergency operation’ (fight or flight) is initiated by the periaqueductal gray region of the brain in response to trauma and the system fails to reset once the threat has passed and the person has survived the threat. In this project, we will also determine if the mode of operation is the same for long COVID and POTS or different.“

“Our current thought is that these disorders are disorders of the brain, in which the fight or flight response is activated and persistent with a decrease in the vagal modulation, which keeps the homeostasis in the body,” Gisela Chelimsky said

'To understand the role of the brain and the vagus, we will perform an MRI of the brain to see how the brain connects and also look at inflammation in the brain.”
 
You must log in or register to reply here.
Back
Top Bottom